Policy | May 25, 2021
Cipla to market Roche's Antibody Cocktail in India
The antibody cocktail is to be administered for the treatment of mild to moderate COVID-19
The antibody cocktail is to be administered for the treatment of mild to moderate COVID-19
BALflu is approved by DCGI for emergency use for the treatment of COVID-19
This test is designed for the qualitative detection of nucleic acid from SARS-CoV-2 in the upper and lower respiratory specimens from individuals suspected of COVID-19
The agreement will help ensure wider reach and access to patients in India
The tablets will be manufactured and marketed under Vivimed’s brand name “Favulous” across India
This Emergency Use Authorisation will now enable Roche to import the globally manufactured product batches to India
First company in the world to launch Ryaltris-AZ, as a novel fixed dose combination of Mometasone furoate 50 mcg + Azelastine 140 mcg
Molnupiravir is an investigational oral antiviral drug currently being studied in a Phase 3 trial for the treatment of non-hospitalized patients with confirmed COVID-19
The drug is approved for the treatment in metastatic colorectal carcinoma, metastatic breast cancer and ovarian, cervical and renal cancer
Apart from the above, it was also decided that Basic Customs Duty on import of COVID-19 vaccines be also exempted with immediate effect for a period of 3 months
Subscribe To Our Newsletter & Stay Updated
